GTS Securities LLC Purchases Shares of 97,558 Takeda Pharmaceutical Company Limited (NYSE:TAK)

GTS Securities LLC purchased a new position in Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 97,558 shares of the company's stock, valued at approximately $1,292,000.

Other hedge funds have also modified their holdings of the company. Farther Finance Advisors LLC increased its stake in shares of Takeda Pharmaceutical by 123.6% in the fourth quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock worth $47,000 after acquiring an additional 1,976 shares during the last quarter. Crowley Wealth Management Inc. acquired a new position in shares of Takeda Pharmaceutical in the fourth quarter worth $52,000. Cromwell Holdings LLC acquired a new position in shares of Takeda Pharmaceutical in the fourth quarter worth $61,000. Venturi Wealth Management LLC boosted its holdings in Takeda Pharmaceutical by 554.7% in the fourth quarter. Venturi Wealth Management LLC now owns 5,028 shares of the company's stock worth $67,000 after purchasing an additional 4,260 shares in the last quarter. Finally, Lindbrook Capital LLC boosted its holdings in Takeda Pharmaceutical by 65.0% in the fourth quarter. Lindbrook Capital LLC now owns 5,151 shares of the company's stock worth $68,000 after purchasing an additional 2,029 shares in the last quarter. 9.17% of the stock is owned by institutional investors and hedge funds.

Takeda Pharmaceutical Stock Up 1.0%

NYSE:TAK traded up $0.15 during trading hours on Friday, reaching $14.95. The company's stock had a trading volume of 567,818 shares, compared to its average volume of 1,930,635. The company has a market cap of $47.55 billion, a price-to-earnings ratio of 37.39, a price-to-earnings-growth ratio of 0.24 and a beta of 0.26. Takeda Pharmaceutical Company Limited has a one year low of $12.58 and a one year high of $15.43. The business's 50-day moving average is $14.66 and its 200-day moving average is $14.04. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.16 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.24 by ($0.08). Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. The firm had revenue of $7.34 billion for the quarter, compared to the consensus estimate of $8.02 billion. Equities research analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

Wall Street Analyst Weigh In

Separately, Morgan Stanley upgraded shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a report on Wednesday, April 2nd.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.